Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease-Reference-Cited by-同舟云学术

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Published:2021-01-05 Issue:6 Volume:109 Page:1631-1638
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Koomen Jeroen V.¹,Stevens Jasper¹,Bakris George²,Correa‐Rotter Ricardo³,Hou Fan Fan⁴,Kitzman Dalane W.⁵,Kohan Donald E.⁶,Makino Hirofumi⁷,McMurray John J. V.⁸,Parving Hans‐Henrik⁹¹⁰,Perkovic Vlado¹¹,Tobe Sheldon W.¹²,Zeeuw Dick¹,Heerspink Hiddo J. L.¹¹¹

Affiliation:

1. Department Clinical Pharmacy and Pharmacology University of GroningenUniversity Medical Center Groningen Groningen The Netherlands

2. American Society of Hypertension Comprehensive Hypertension Center University of Chicago Medicine and Biological Sciences Chicago Illinois USA

3. National Medical Science and Nutrition Institute Salvador Zubirán Mexico City Mexico

4. Division of Nephrology Nanfang Hospital Southern Medical University National Clinical Research Center for Kidney Disease Guangzhou China

5. Wake Forest School of Medicine Winston‐Salem North Carolina USA

6. Division of Nephrology University of Utah Health Sciences Center Salt Lake City Utah USA

7. Okayama University Okayama Japan

8. British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK

9. Department of Medical Endocrinology Rigshospitalet University of Copenhagen Copenhagen Denmark

10. Faculty of Health Science Aarhus University Aarhus Denmark

11. George Institute for Global Health and University of New South Wales Sydney New South Wales Australia

12. Division of Nephrology Sunnybrook Health Sciences Centre University of Toronto and the Northern Ontario School of MedicineToronto Ontario Canada

Funder

Novo Nordisk Fonden

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

AbbVie

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2143

Reference12 articles.

1. The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

2. Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy

3. Avosentan for Overt Diabetic Nephropathy

4. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

5. Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease;Clinical Kidney Journal;2024-03-19

2. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation;Biomedicine & Pharmacotherapy;2023-03

3. Novel strategies in nephrology: what to expect from the future?;Clinical Kidney Journal;2022-09-20

4. Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease;Clinical Pharmacology & Therapeutics;2022-08-11